Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Waterstone Pharmaceuticals (Wuhan) Co. Ltd. manages a company patent portfolio focused on the Biotechnology & Pharmaceuticals technology area. There is 1 pending office action currently active within the portfolio. The prosecution involves 1 distinct examiner and 1 distinct art unit. This concentration suggests that the company's current patenting activity is not diversified across different examination groups. For a Biotechnology & Pharmaceuticals portfolio with 1 pending office action, the prosecution strategy is inherently tied to 1 technical review path.
The busiest examiner for these filings is SONG, JIANFENG, who is responsible for 1 busiest examiner pending office action. Because the total pending office actions for the Biotechnology & Pharmaceuticals sector is 1, this examiner handles the full extent of the company's current workload. This point of contact in the patent office defines the current prosecution landscape for the entity. Any progress in the portfolio will be directly attributable to the interactions between the applicant and SONG, JIANFENG within the 1 distinct art unit assigned to the case.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SONG, JIANFENG | 1 | 56.4% | +33.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260067 | PHARMACEUTICAL POLYMER FOR TREATING HYPERKALEMIA AND PREPARATION METHOD THEREOF | SONG, JIANFENG | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18260067 | PHARMACEUTICAL POLYMER FOR TREATING HYPERKALEMIA AND PREPARATION METHOD THEREOF | SONG, JIANFENG | 1613 | §103 | Final Rejection | — | Pending | Jun 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialWaterstone Pharmaceuticals (Wuhan) Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jianfeng Song has the most, with 1 of Waterstone Pharmaceuticals (Wuhan) Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
